Stock data
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of US$14.34B and net income of US$4.50B for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$14.34B | — | US$3.58B | US$4.50B | — |
| 2024 | US$14.20B | — | US$3.99B | US$4.41B | — |
| 2023 | US$13.12B | — | US$4.05B | US$3.95B | — |
| 2022 | US$12.17B | — | US$4.74B | US$4.34B | — |
| 2021 | US$16.07B | — | US$8.95B | US$8.08B | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$4.29B | US$1.30B | — |
| 2026-03-31 | US$3.61B | US$727.20M | — |
| 2025-12-31 | US$3.88B | US$844.60M | — |
| 2025-09-30 | US$3.75B | US$1.46B | — |
| 2025-06-30 | US$3.68B | US$1.39B | — |
| 2025-03-31 | US$3.03B | US$808.70M | — |
| 2024-12-31 | US$3.79B | US$917.70M | — |
| 2024-09-30 | US$3.72B | US$1.34B | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.